Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Amicus Therapeutics to Present at Leerink Swann Rare Disease Roundtable



Amicus Therapeutics to Present at Leerink Swann Rare Disease Roundtable

CRANBURY, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief
Executive Officer, will present a corporate overview at the Leerink Swann Rare
Disease Roundtable in New York, NY on Wednesday, October 2, 2013 at 1:20 p.m.
ET.

A live webcast of the presentation can be accessed through the Investors
section of the Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
 

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe
disease.                                                                             

FOLD-G

CONTACT: Amicus Therapeutics
         Sara Pellegrino
         (609) 662-5044
         spellegrino@amicusrx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement